IDEAYA initiates Phase 1/2 Part 2 monotherapy expansion for IDE892 in MTAP-deleted cancers

PUBT · 2d ago
IDEAYA initiates Phase 1/2 Part 2 monotherapy expansion for IDE892 in MTAP-deleted cancers
  • IDEAYA initiated Part 2 monotherapy expansion in its Phase 1/2 study of IDE892 for MTAP-deleted pancreatic cancer, NSCLC.
  • Dose escalation cleared multiple cohorts; projected efficacious exposures reached with 24-hour EC90 target coverage; maximum tolerated dose not yet reached.
  • IDE892 positioned as a combination partner; escalation continues with IDE397 in MTAP NSCLC, PDAC; pan-RAS combination first-patient-in targeted H2 2026.
  • Company targets a MTAP/CDKN2A, KRAS, pancreatic cancer R&D Day in Q4 2026; CDKN2A program targets IND in H1 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IDEAYA Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607270600PR_NEWS_USPR_____SF11839) on July 27, 2026, and is solely responsible for the information contained therein.